Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Slightly Bullish +25

Amgen Stock (AMGN) Opinions on Congressional Trade Disclosure - Quiver Quantitative

📈 Representative David J. Taylor added Amgen shares to his portfolio in early June, signaling a preference for stable cash-flow generators.

💰 Amgen reported Q1 2026 revenues of $8.6 billion, marking a 5.76% increase from the prior year.

📉 Insider trading data shows executives have sold shares four times in the past six months with zero purchases.

🏛️ Congressional trading activity includes Representative Maria Elvira Salazar making one purchase and one sale totaling $100,000.

📊 Institutional investors show divergent views, with Capital World Investors adding 6.2M shares while Capital International removed 11M shares.

🎯 Analyst price targets range from a low of $327 by Truist Securities to a high of $427 by Piper Sandler.

📉 The median analyst price target for Amgen is set at $350.00 across 14 analysts in the last six months.

Bullish Signals
  • Amgen achieved a 5.76% revenue growth in Q1 2026, reaching $8.6 billion.
  • Representative David J. Taylor initiated new positions in Amgen, viewing it as a stable cash-flow generator.
  • Capital World Investors increased their position by 26.8%, adding over 6 million shares.
  • Geode Capital Management added 1.1 million shares to its portfolio, increasing holdings by 7.9%.
  • Piper Sandler analyst David Amsellem set a high price target of $427, indicating strong growth potential.
Risk Factors
  • Amgen insiders have executed four sales totaling over $21 million in the past six months with no purchases.
  • Capital International Investors significantly reduced their position by removing 11 million shares (-60.8%).
  • JPMorgan Chase & Co. decreased its holdings by 45.8%, removing nearly 2 million shares.
  • Rockefeller Capital Management L.P. cut its position by 71.9%, exiting a significant portion of its stake.
  • Pacer Advisors, Inc. completely exited its position, removing all 1.6 million shares held.
Full Analysis
Amgen (AMGN) is the subject of recent market activity driven by a congressional portfolio shift and insider trading data. Representative David J. Taylor added Amgen shares to his holdings in early June, interpreted by observers as a preference for stable cash-flow generators amidst broader market rotations. While social media sentiment reflects measured optimism regarding the biotech sector's defensive qualities, the article notes that insiders have sold more than they have purchased over the last six months. Financial performance and institutional ownership data provide further context to the stock's current standing. Amgen reported Q1 2026 revenues of $8.6 billion, representing a 5.76% increase year-over-year. Institutional investor activity has been mixed in the most recent quarter, with significant additions from Capital World Investors and Geode Capital Management offset by substantial reductions from Capital International Investors and JPMorgan Chase. Analyst price targets for Amgen vary across major financial institutions, reflecting a range of valuations for the company's future prospects. Recent targets include $340 from Morgan Stanley and Guggenheim, $427 from Piper Sandler, and $400 from UBS. The median analyst target stands at $350.00, suggesting a consensus valuation that balances growth expectations with current market conditions.